ACST News and Press, Acasti Pharma Inc. From 06/29/20

Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment  as likely contributor to unusually high placebo effect in TRILOGY 1 Acasti management to host conference call at 1 PM ET today LAVAL, Quebec, June 29, 2020 (GLOBE ...

Acasti Pharma (NASDAQ: ACST ) will host a conference cal l on Monday, June 29, at 1:00 pm ET to provide more details on its post hoc analyses of the failed Phase 3 TRILOGY 1 study evaluating CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia (high levels of triglycerid...

LAVAL, Québec, June 19, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate C...

Penny Stocks To Watch Right Now The stock market is moving higher again today and so are penny stocks . Continued hope about the economic turnaround has investors focusing on a very specific piece of the headline flow on Wednesday. I’ve had conversations with people that don’t &...

FDA response expected on or before June 30, 2020 Acasti also received notice of issuance of a Composition of Matter Patent in Hong Kong LAVAL, Quebec, April 30, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST –...

LAVAL, Québec, April 20, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate ...

LAVAL, Québec, April 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and   commercialization of its prescription dru...

Patent upheld in Japan following opposition filings and subsequently allowed Completes TRILOGY 1 audits and accelerates plans to submit FDA meeting request by the end of March LAVAL, Québec, March 11, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the &...

LAVAL, Québec, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate C...

Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...